CACNA1E
ENSG00000198216
Target class
Ion channel
Chromosome
1
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNA1E
- Gene name
- Calcium voltage-gated channel subunit alpha1 E
- Gene symbol
- CACNA1E
- Previous gene symbols
- CACNL1A6
- Protein name
- Voltage-dependent R-type calcium channel subunit alpha-1E (Brain calcium channel II) (BII) (Calcium channel, L type, alpha-1 polypeptide, isoform 6) (Voltage-gated calcium channel subunit alpha Cav2.3)
- Cav2.3
- BII
- CACH6
- Gene biotype
- Protein coding
- Gene family
- EF-hand domain containing|Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 20.32
- Tissue specificity (Gini)
- 0.797
- Tissue specificity (tau)
- 0.915
- KEGG gene identifiers
- hsa:777
- Protein interaction confidence
- 0.858913
- Protein interaction partners
- 23
- R-HSA-112308
- R-HSA-422356
- End position
- 181813262
- Start position
- 181317690
- Chromosome
- 1
- Strand
- Forward
- Membrane
- Multi-pass membrane protein .
- Actin filaments
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.914751
- Expression inequality (Gini)
- 0.796851
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 20.32
- Brain - Caudate (basal ganglia)
- 11.86
- Brain - Cortex
- 11.29
- Brain - Frontal Cortex (BA9)
- 10.47
- Brain - Putamen (basal ganglia)
- 8.25
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)20.32
- Brain - Caudate (basal ganglia)11.86
- Brain - Cortex11.29
- Brain - Frontal Cortex (BA9)10.47
- Brain - Putamen (basal ganglia)8.25
- Brain - Anterior cingulate cortex (BA24)7.69
- Brain - Cerebellum6.66
- Brain - Hippocampus6.27
- Brain - Hypothalamus6.18
- Brain - Cerebellar Hemisphere6.14
- Brain - Amygdala4.43
- Cells - EBV-transformed lymphocytes4.14
- Whole Blood1.59
- Testis1.46
- Brain - Substantia nigra1.4
- Brain - Spinal cord (cervical c-1)0.59
- Kidney - Cortex0.53
- Kidney - Medulla0.52
- Spleen0.5
- Colon - Sigmoid0.23
- Pituitary0.16
- Heart - Atrial Appendage0.13
- Small Intestine - Terminal Ileum0.13
- Lung0.13
- Fallopian Tube0.12
And 29 more, listed on the interactive page.
Biological processes
- GO:0007268
- GO:0005886
- GO:0005891
- GO:0005245
- GO:0022843
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker